Plus updates financial and cash guidance for 2024

Plus receives $3.3m in grant revenue in q4 2023 forecasts additional $6.9m of grant revenue for 2024 enters into debt restructuring deal with pershing capital to reduce 2024 cash burn by $3.7m austin, texas, dec. 18, 2023 (globe newswire) -- plus therapeutics, inc. (nasdaq:  pstv ) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced financial updates and guidance for 2024. plus is currently in the second year of a cancer prevention and research institute of texas (cprit) award totaling $17.8 million.
PSTV Ratings Summary
PSTV Quant Ranking